Skip to main content
SpringerLink
Log in

Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer

Medical Oncology volume 33, Article number: 27 (2016) Cite this article

Abstract

In breast cancer, there are two widely used paclitaxel-based adjuvant chemotherapies, either dose dense paclitaxel (ddP) or weekly paclitaxel (wP). To our knowledge, the comparisons of toxicity and tolerability between the two regimens have never been reported in the literature. This is a retrospective single-institution charts review of breast cancer patients who were treated with paclitaxel-based chemotherapy either ddP or wP. In total, 76 and 45 patients with breast cancer received adjuvant standard ddP and wP, respectively. Patient characteristics in both groups were comparable. Our results showed no statistical significant difference in toxicity profile and tolerability between the two regimens. Particularly, chemotherapy-induced peripheral neuropathy (CIPN) was equally observed in both schedules. Furthermore, grade 3 and 4 CIPN was observed in 17 and 18 %, respectively (p = 0.93). In terms of tolerability, both regimens resulted in similar rates of hospitalization and treatment discontinuation. Our data analysis indicates no significant difference in toxicity profile between the two standard paclitaxel regimens in breast cancer. However, this is a small sample-sized retrospective study and further prospective trial with a larger sample size is warranted.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (Canada)

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet. 2012;379(9814):432–44.

    Article  Google Scholar 

  2. Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):CD004421.

  4. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75(4):659–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004–14.

    Article  CAS  PubMed  Google Scholar 

  6. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–9.

    Article  PubMed  Google Scholar 

  7. Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132–8.

    Article  CAS  PubMed  Google Scholar 

  8. Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013;9(5):234–40.

    Article  Google Scholar 

  9. Tulsyan S, Chaturvedi P, Singh AK, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene. 2014;543(1):69–75.

    Article  CAS  PubMed  Google Scholar 

  10. Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:240.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E III. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90(16):1205–11.

    Article  CAS  PubMed  Google Scholar 

  12. Goldhirsch WC, Wood RD, Gelber AS, Coates B, Thürlimann HJ, Senn A. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133–44.

    Article  CAS  PubMed  Google Scholar 

  13. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014;12:542–90.

    CAS  PubMed  Google Scholar 

  14. Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and Leukemia Group B 40101. J Clin Oncol. 2012;30:4071–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.

    Article  CAS  PubMed  Google Scholar 

  16. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR. Hortobagyi GN.SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015;33(1):58–64.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Rossi L, Tomao F, Lo Russo G, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S. Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag. 2013;9:457–62.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJ, Mantyh P, Dyck PJ. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Int J Clin Oncol. 2013;18(1):132–8.

    Article  Google Scholar 

  19. Badalucco S, Reed KK. Supporting quality and patient safety in cancer clinical trials. Clin J Oncol Nurs. 2011;15(3):263–5.

    Article  PubMed  Google Scholar 

  20. Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340–7.

    Article  CAS  PubMed  Google Scholar 

  21. Sugarman S, Wasserheit C, Hodgman E, et al. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat. 2009;115(3):609–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Joan C. Edwards School of Medicine, Marshall University, 1400 Hal Greer Blvd., Huntington, WV, 25701, USA

    Mohamed Alsharedi, Todd Gress, Jennifer Dotson, Nabiha Elmsherghi & Maria Tria Tirona

Authors
  1. Mohamed Alsharedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Todd Gress
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer Dotson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nabiha Elmsherghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Tria Tirona
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Alsharedi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alsharedi, M., Gress, T., Dotson, J. et al. Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer. Med Oncol 33, 27 (2016). https://doi.org/10.1007/s12032-016-0740-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0740-1

Keywords

Search

Navigation